Recommended Readings: James P. Allison, Ph.D., Friday May 12th, 2017

Friday Lectures

Friday, May 2, 2017  3:45 p.m.

Caspary Auditorium

James P. Allison, Ph.D.

Professor and Vivian L. Smith Distinguished Chair of Immunology,

Executive Director of the Immunotherapy Platform

The University of Texas MD Anderson Cancer Center

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities, and Prospects for a Cure

Recommended Readings:

Hazarika M; Chuk MK; Theoret MR; et al. (2017). U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.CLINICAL CANCER RESEARCH. doi: 10.1158/1078-0432

Medina, Patrick J.; Adams, Val R. (2016). PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. PHARMACOTHERAPY. 36(3): 317-334

Sharma, Padmanee; Allison, James P. (2015). Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. CELL. 161(2): 205-214

Robert, Caroline; Schachter, Jacob; Long, Georgina V.; et al. (2015). Pembrolizumab versus Ipilimumab in Advanced Melanoma. NEW ENGLAND JOURNAL OF MEDICINE    372(26): 2521-2532

Sharma, Padmanee; Allison, James P. (2015). The future of immune checkpoint therapy. SCIENCE. 348(6230): 56-61

Gubin, Matthew M.; Zhang, Xiuli; Schuster, Heiko; et al. (2014). Checkpoint blockage cancer immunotherapy targets tumour-specific mutant antigens. NATURE. 515(7528): 577-+

Lipson, Evan J.; Drake, Charles G. (2011). Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. CLINICAL CANCER RESEARCH. 17(22): 6958-6962


Recommended Readings: Edith Heard, Ph.D., Friday, April 21, 2017

Friday Lectures

Friday, April 21, 2017   3:45 p.m.

Caspary Auditorium

Edith Heard, Ph.D.

Professor and Chair, Epigenetics and Cellular Memory, Collège de France

Director, Department of Genetics and Developmental Biology

Institut Curie

The Epigenetic Dynamics of X-chromosome Inactivation: Fine-tuning Gene Dosage during Development

Recommended Readings:

da Rocha, Simao T.; Heard, Edith (2017). Novel players in X inactivation: insights into Xist-mediated gene silencing and chromosome conformation. NATURE STRUCTURAL & MOLECULAR BIOLOGY. 24(3): 197-204

Borensztein, Maud; Syx, Laurene; Ancelin, Katia; et al. (2017). Xist-dependent imprinted X inactivation and the early developmental consequences of its failure. NATURE STRUCTURAL & MOLECULAR BIOLOGY. 24(3): 226-+

Giorgetti, Luca; Lajoie, Bryan R.; Carter, Ava C.; et al. (2016). Structural organization of the inactive X chromosome in the mouse. NATURE. 535(7613): 575-+

Wu, Hao; Luo, Junjie; Yu, Huimin; et al. (2014). Cellular Resolution Maps of X Chromosome Inactivation: Implications for Neural Development, Function, and Disease. NEURON. 81(1): 103-119

Gendrel, Anne-Valerie; Heard, Edith (2014). Noncoding RNAs and Epigenetic Mechanisms During X-Chromosome Inactivation.  ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY. 30: 561-580

Nora, Elphege P.; Lajoie, Bryan R.; Schulz, Edda G.; et al. (2012). Spatial partitioning of the regulatory landscape of the X-inactivation centre. NATURE. 485(7398): 381-385

Recommended Readings: Joseph Schlessinger, Ph.D., May 13

Friday Lecture Series
Friday, May 13, 2016
3:45 p.m., Caspary Auditorium

Joseph Schlessinger, Ph.D.
William H. Prusoff Professor and Chair,
Department of Pharmacology,
Yale School of Medicine

Cell Signaling by Receptor Tyrosine Kinases: From Basic Principles to Cancer Therapy

Recommended Readings:

Empirical Articles

Bae, J. H., Lew, E. D., Yuzawa, S., Tomé, F., Lax, I., & Schlessinger, J. (2009). The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell, 138(3), 514-524. doi: 10.1016/j.cell.2009.05.028.

Chung, I., Akita, R., Vandlen, R., Toomre, D., Schlessinger, J., & Mellman, I. (2010). Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature, 464(7289), 783-787. doi: 10.1038/nature08827.

Yuzawa, S., Opatowsky, Y., Zhang, Z., Mandiyan, V., Lax, I., & Schlessinger, J. (2007). Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell, 130(2), 323-334.

Review Papers

Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117-1134. doi: 10.1016/j.cell.2010.06.011.

Schlessinger, J. (2014). Receptor tyrosine kinases: legacy of the first two decades. Cold Spring Harbor Perspectives in Biology, 6(3), a008912. doi: 10.1101/cshperspect.a008912.

Recommended Readings: Tony Hunter, Ph.D., April 29

Friday Lecture Series
Friday, April 29, 2016
3:45 p.m., Caspary Auditorium

Tony Hunter, Ph.D.
Director, Molecular and Cell Biology Laboratory,
Renato Dulbecco Chair in Cancer Research,
American Cancer Society Professor,
Salk Institute for Biological Studies

Post-translational regulation of cell signaling

Recommended Readings

Hunter, T. (2014). The genesis of tyrosine phosphorylation. Cold Spring Harbor Perspectives in Biology, 6(5), a020644. doi: 10.1101/cshperspect.a020644

Hunter, T. (2015). Discovering the first tyrosine kinase. Proceedings of the National Academy of Sciences, 112(26), 7877–7882. doi: 10.1073/pnas.1508223112

Recommended Readings: Lydia Finley, Ph.D., March 30

Special Lecture
Wednesday, March 30
4:00 p.m., Carson Family Auditorium (CRC)

Lydia Finley, Ph.D.
Jack Sorrell Fellow,
Damon Runyon Cancer Research Foundation,
Cancer Biology and Genetics Program,
Memorial Sloan Kettering Cancer Center

Metabolic Regulation of Cell Fate Decisions

Recommended Readings

Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D., & Thompson, C. B. (2015). Intracellular [agr]-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature, 518(7539), 413-416.  doi: 10.1038/nature13981.

Intlekofer, A. M., Dematteo, R. G., Venneti, S., Finley, L. W., Lu, C., Judkins, A. R., … & Thompson, C. B. (2015). Hypoxia induces production of L-2-hydroxyglutarate, Cell Metabolism, 22(2), 304-311. doi: 10.1016/j.cmet.2015.06.023.

Jeong, S. M., Xiao, C., Finley, L. W., Lahusen, T., Souza, A. L., Pierce, K., … & Xu, X. (2013). SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell, 23(4), 450-463. doi: 10.1016/j.ccr.2013.02.024.

Laurent, G., de Boer, V. C., Finley, L. W., Sweeney, M., Lu, H., Schug, T. T., … & Haigis, M. C. (2013). SIRT4 represses peroxisome proliferator-activated receptor α activity to suppress hepatic fat oxidation. Molecular and Cellular Biology, 33(22), 4552-4561. doi: 10.1128/MCB.00087-13.

Recommended Readings: Mitzi Kuroda, Ph.D., November 20th

Friday Lecture Series
Friday, November 20, 2015
3:45 p.m., Caspary Auditorium

Mitzi Kuroda, Ph.D.
Professor of Medicine,
Departments of Genetics and Medicine,
Brigham & Women’s Hospital,
Harvard Medical School

Nucleation and Spreading of Chromatin Domains in Epigenetic Models and in Cancer

Recommended Readings

Empirical Articles 

Alekseyenko, A. A., Gorchakov, A. A., Kharchenko, P. V., & Kuroda, M. I. (2014). Reciprocal interactions of human C10orf12 and C17orf96 with PRC2 revealed by BioTAP-XL cross-linking and affinity purification. Proceedings of the National Academy of Sciences, 111(7), 2488-2493. doi: 10.1073/pnas.1400648111

Alekseyenko, A. A., Gorchakov, A. A., Zee, B. M., Fuchs, S. M., Kharchenko, P. V., & Kuroda, M. I. (2014). Heterochromatin-associated interactions of Drosophila HP1a with dADD1, HIPP1, and repetitive RNAs. Genes & Development, 28(13), 1445-1460. doi: 10.1101/gad.241950.114

Alekseyenko, A. A., Walsh, E. M., Wang, X., Grayson, A. R., Hsi, P. T., Kharchenko, P. V., … & French, C. A. (2015). The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains. Genes & Development, 29(14), 1507-1523. doi: 10.1101/gad.267583.115

Review Paper

McElroy, K. A., Kang, H., & Kuroda, M. I. (2014). Are we there yet? Initial targeting of the Male-Specific Lethal and Polycomb group chromatin complexes in Drosophila. Open biology, 4(3), 140006. doi: 10.1098/rsob.140006

Recommended Readings: Denes Hnisz, Ph.D., October 12th

Special Lecture
Monday, October 12th, 2015
4:00 p.m., Carson Family Auditorium (CRC)

Denes Hnisz, Ph.D.
Postdoctoral Fellow,
Whitehead Institute for Biomedical Research

Transcriptional Regulatory Mechanisms Defining Cell Identity

Recommended Readings

Dowen, J. M., Fan, Z. P., Hnisz, D., Ren, G., Abraham, B. J., Zhang, L. N., … & Young, R. A. (2014). Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes. Cell, 159(2), 374-387. doi:10.1016/j.cell.2014.09.030.

Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., … & Young, R. A. (2013). Super-enhancers in the control of cell identity and disease. Cell, 155(4), 934-947. doi:10.1016/j.cell.2013.09.053.

Hnisz, D., Schuijers, J., Lin, C. Y., Weintraub, A. S., Abraham, B. J., Lee, T. I., … & Young, R. A. (2015). Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Molecular Cell, 58(2), 362-370. doi:10.1016/j.molcel.2015.02.014.

Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., … & Young, R. A. (2013). Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell, 153(2), 307-319. doi:10.1016/j.cell.2013.03.035.

Recommended Readings: Carl H. June, M.D., May 22nd

Friday Lecture Series
Friday, May 22, 2015
3:45 p.m., Caspary Auditorium

Carl H. June, M.D.
Director, Translational Research Program,
Abramson Family Cancer Research Institute
Richard W. Vague Professor in Immunotherapy,
Perelman School of Medicine,
University of Pennsylvania

Adoptive Cell Therapy with Engineered T Cells

Recommended Readings

Empirical Articles

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., … & June, C. H. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509-1518.  doi:10.1056/NEJMoa1215134

Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3(95), 95ra73-95ra73. doi:10.1126/scitranslmed.3002842

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. New England Journal of Medicine, 365(8), 725-733. doi:10.1056/NEJMoa1103849

Review Papers

June, C. H., Maus, M. V., Plesa, G., Johnson, L. A., Zhao, Y., Levine, B. L., … & Porter, D. L. (2014). Engineered T cells for cancer therapy. Cancer Immunology, Immunotherapy, 63(9), 969-975. doi:10.1007/s00262-014-1568-1

Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014). Adoptive immunotherapy for cancer or viruses. Annual Review of Immunology, 32, 189-225. doi:10.1146/annurev-immunol-032713-120136

Recommended Readings: Jos Jonkers, Ph.D., March 20

Friday Lecture Series
Friday, March 20, 2015
3:45 p.m., Caspary Auditorium

Jos Jonkers, Ph.D.
Head, Division of Molecular Pathology,
Netherlands Cancer Institute

Unraveling Therapy Response and Resistance in Mouse Models of Human Breast Cancer

Recommended Readings

Empirical Articles

Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., … & Jonkers, J. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural & Molecular Biology, 17(6), 688-695. doi:10.1038/nsmb.1831.

Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., & Berns, A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genetics, 29(4), 418-425. doi:10.1038/ng747

Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., … & Jonkers, J. (2007). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proceedings of the National Academy of Sciences, 104(29), 12111-12116. doi:10.1073/pnas.0702969104

Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O., Zander, S. A., … & Jonkers, J. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences, 105(44), 17079-17084. doi:10.1073/pnas.0806092105

Review Papers

Bouwman, P., & Jonkers, J. (2014). Molecular Pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors?. Clinical Cancer Research, 20(3), 540-547. doi:10.1158/1078-0432.CCR-13-0225

Klarenbeek, S., van Miltenburg, M. H., & Jonkers, J. (2013). Genetically engineered mouse models of PI3K signaling in breast cancer. Molecular Oncology, 7(2), 146-164. doi:10.1016/j.molonc.2013.02.003

Recommended Readings: Louis M. Staudt, M.D., Ph.D. January 9

Friday Lecture Series
Friday, January 9, 2015
3:45 p.m., Caspary Auditorium

Louis M. Staudt, M.D., Ph.D.
Director, Center for Cancer Genomics
Co-chief, Lymphoid Malignancies Branch
Head, Molecular Biology of Lymphoid Malignancies Section,
Center for Cancer Research,
National Cancer Institute at the National Institutes of Health

Therapy of Lymphoma Inspired by Functional and Structural Genomics

Recommended Readings

Empirical Articles

Alizadeh, A., Eisen, M., Davis, R., & Ma, C. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(6769), 503-511.

Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., … Staudt, L. M. (2006). A loss-of-function RNA interference screen for molecular targets in cancer. Nature, 441(7089), 106–110. doi:10.1038/nature04687

Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., … Staudt, L. M. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346(25), 1937–1947. doi:10.1056/NEJMoa012914

Yang, Y., III, A. S., Emre, N., & Ceribelli, M. (2012). Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell, 21(6), 723–737. doi:10.1016/j.ccr.2012.05.024.Exploiting

Review Papers

Lenz, G., & Staudt, L. M. (2010). Aggressive lymphomas. The New England Journal of Medicine, 362(15), 1417–1429. doi:10.1056/NEJMra0807082

Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012). Pathogenesis of human B cell lymphomas. Annual Review of Immunology, 30, 565–610. doi:10.1146/annurev-immunol-020711-075027